10 results about "Latanoprost" patented technology

The application provides a use of a combination of metoclopramide and latanoprost for preparing an anticoagulant drug, and belongs to the technical field of biological medicines. It is accidentally found that the anticoagulant effect of patients with deep vein thrombosis combined with high intraocular pressure is improved after long-term continuous oral administration of metoclopramide. Thanks to this beneficial discovery, the application realizes good anticoagulant effect by applying the latanoprost liniment in a topical manner on the basis of oral administration of metoclopramide. The application is convenient to administer, has definite and sustained curative effect, and is safe and reliable. The application expands the optional range of anticoagulant drugs, and realizes better curative effect at the same time, and has outstanding technical advantages and wide popularization prospect.

The application discloses application of latanoprost nitrate in preparation of a therapeutic drug for a disease related to new coronavirus infection. According to the research of the application, the latanoprost nitrate has a strong effect of inhibiting RNA-dependent RNA polymerase of the new coronavirus, has significant antiviral activity on the new coronavirus, and the latanoprost nitrate is an existing clinical drug, and therefore has important application value in development of an anti-new coronavirus infection drug.

The present invention relates to the topical pharmaceutical composition comprising about 0.001% w / w to about 1% w / w latanoprost and about 1% w / w to about 15% w / w cortexolone-17α-propionate and a pharmaceutically acceptable vehicle comprising one or more solvent and process of its preparation. The invention further relates to the method wherein the composition is suitable for preventing and / or treating hair loss and / or stimulating hair growth. in patients suffering from alopecia, in particular androgenic alopecia (AGA).

A method for reducing a subcutaneous fat deposit or a visceral fat deposit in vivo by contacting the fat deposit with a composition of latanoprost encapsulated in a liposome formed solely of egg phosphatidylcholine (EggPC) or palmitoyloleoyl phosphatidylcholine (POPC). Also disclosed are methods for treating steatoblepharon, proptosis, and obstructive sleep apnea associated with excess upper airway fat by injecting into the eyelid, intraconal space, and upper airway fat deposit, respectively, the composition of latanoprost encapsulated in an EggPC or POPC liposome.

Topical compositions and kits are provided for hair regrowth, hair loss prevention, and scalp health improvement. These formulations contain at least one active (e.g., finasteride, minoxidil, dutasteride, and latanoprost), at least one penetration enhancer (e.g., Transcutol®, laurocapram), stabilizers, and anti-inflammatory agents like retinoic acid, hydrocortisone, and aloe vera. They utilize optimized particle sizes (D90 ≤8.5 μm, span ≤1.7) and may include bioadhesive polymers or nanoparticles for enhanced follicular delivery and extended residence. Modular kits offer multi-chambered packaging, calibrated droppers, and app- or sensor-guided dispensing for customizable ingredient mixing and regimen personalization. These innovations improve active stability, minimize irritation, and yield superior clinical outcomes (hair density and quality) over traditional therapies. Methods include treating varied alopecia types, with or without device-assisted delivery (microneedling, light therapy), alongside digital monitoring, compliance tracking, and optional diagnostic or conditioning tools for individualized scalp and hair care.

The present invention relates to the use of combination of 5α-reductase inhibitors and prostaglandin analogues for preventing hair loss and / or stimulating hair growth. The present invention also relates to topical composition containing 5α-reductase inhibitors and prostaglandin analogues for preventing hair loss and / or stimulating hair growth on the scalp. The present invention also relates to composition and methods for treating certain hair loss disorders such as androgenetic alopecia.

The invention discloses a preparation process of latanoprost, bemeprost and intermediates of the latanoprost and the bemeprost. Specifically, the invention provides a preparation method of a compound as shown in a formula IV, which comprises the following steps: in the presence of alkali and a solvent, carrying out wittig reaction on a compound as shown in a formula III and 4-carboxybutyl triphenylphosphonium bromide to generate the compound as shown in the formula IV, wherein the molar ratio of the compound shown in the formula III to the alkali is 1: (11-20); the reaction temperature of the wittig reaction is-40 DEG C to-5 DEG C. The preparation process provided by the invention has the advantages of high product purity, high yield and simple separation, and is suitable for industrial production.

A liquid pharmaceutical composition for use in the topical treatment of androgenetic alopecia in a patient in need thereof, the composition comprising 2.5 mg / ml latanoprost, at least 85% (v / v) 1-perfluorohexyloctane (F6H8) and about 8 to 12% (v / v) isopropanol, wherein the composition is in form of a solution.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a sustained-release latanoprost ophthalmic gel preparation and a preparation method thereof. The gel preparation is prepared from the following components in percentage by weight: 0.001 to 0.01 percent of latanoprost; 1-3% of an organic solvent; the balance is a gel matrix; wherein the gel matrix is prepared from the following components in percentage by weight: 10 to 20 percent of modified polyethylene caprolactam-polyvinyl acetate-polyethylene glycol grafted copolymer; 1-2% of an oleate compound; the balance is an isoosmotic pressure phosphate buffer solution; the gel preparation provided by the invention is slow and lasting in in-vitro release behavior, has a long-acting slow-release effect, has a good intraocular pressure reducing effect on rats, has a good treatment effect, does not have cornea toxicity after being used for a long time, and is high in safety.

A latanoprost ophthalmic gel, comprising the following raw materials: 0.001-0.01% of latanoprost, 0.01-0.1% of a gel matrix, 0.1-5.0% of a nonionic surfactant, 0.1-5.0% of an osmotic pressure regulator, 0.01-1.0% of a pH regulator, and the balance of water for injection. The raw materials do not comprise a bacteriostatic agent. Not adding the bacteriostatic agent can fundamentally eliminate toxic side effects caused by the bacteriostatic agent, avoid adverse reactions to users, and improve product safety; and the non-ionic surfactant can form nanomicelles during the preparation process of the gel to exert a solubilizing effect, so as to overcome the problems of reduced solubility and poor stability of latanoprost caused by the absence of the bacteriostatic agent.